Insider Buying: Vita Life Sciences Limited (ASX:VLS) Insider Purchases 11,090 Shares of Stock

Vita Life Sciences Limited (ASX:VLS) insider Peter Osborne purchased 11,090 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was bought at an average price of A$1.73 ($1.11) per share, for a total transaction of A$19,185.70 ($12,298.53).

Peter Osborne also recently made the following trade(s):

• On Monday, February 24th, Peter Osborne acquired 4,820 shares of Vita Life Sciences stock. The shares were bought at an average cost of A$1.92 ($1.23) per share, for a total transaction of A$9,254.40 ($5,932.31).

Vita Life Sciences Price Performance

The firm has a market capitalization of $107.10 million, a P/E ratio of 11.27 and a beta of 0.46. The company has a current ratio of 2.96, a quick ratio of 1.57 and a debt-to-equity ratio of 0.88.

Vita Life Sciences Increases Dividend

The company also recently disclosed a Final dividend, which was paid on Thursday, April 10th. Investors of record on Thursday, April 10th were paid a dividend of $0.065 per share. This represents a dividend yield of 3.42%. The ex-dividend date of this dividend was Thursday, March 20th. This is a positive change from Vita Life Sciences’s previous Final dividend of $0.06. Vita Life Sciences’s payout ratio is 41.18%.

Vita Life Sciences Company Profile

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children's health; antioxidants; bones, joints, and muscles; and eye health.